New hormonal IUD shows promise in early birth control trial

NCT ID NCT00967746

Completed Disease control Sponsor: Organon and Co Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested three different doses of a new hormonal intrauterine system (IUS) releasing etonogestrel against a standard copper IUD for contraception. 84 healthy women who had given birth took part to see how safe and acceptable the devices were, and how they affected vaginal bleeding. The goal was to find the best dose for future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: etonogestrel-releasing intrauterine system (hormonal IUD)
What this could lead to: If successful, this could lead to a new hormonal IUD option for birth control with fewer side effects or better bleeding patterns.
What could go wrong: This is an early phase 2 trial with only 84 participants, so results may not apply to everyone. Different doses may cause unexpected bleeding or side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONTRACEPTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CONTRACEPTION

Contacts and locations

Show contact details

Locations

Dinox GmbH

Berlin, D-10115, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.